

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): **September 20, 2017**

VolitionRx Limited

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of Incorporation)

001-36833
(Commission File Number)

91-1949078
(IRS Employer
Identification Number)

1 Scotts Road
#24-05 Shaw Centre
Singapore 228208
(Address of principal executive offices and Zip Code)

+1 (646) 650-1351
(Registrant's telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

VOLITIONRX LIMITED
Form 8-K
Current Report

Item 1.01 Entry into Material Definitive Agreements.

On September 20, 2017, VolitionRx Limited, a Delaware corporation (the “Company”), and Belgian Volition SPRL, a Belgian corporation (“Belgian Volition”) and wholly-owned subsidiary of the Company, entered into an unsecured loan agreement for an amount up to approximately US\$1.2 million (€1.0 million) (the “Loan Agreement”) with SOFINEX, a Belgian public organization focused on the internationalization of Walloon companies (“SOFINEX”).

The proceeds of the Loan Agreement will be used to support the development of Belgian Volition’s U.S. subsidiary, Volition America, Inc. (“Volition America”). The Loan Agreement provides for a fixed annual interest rate of 4.50%, an approximate 7 year term, including a grace period for principal payments until December 31, 2019, with interest payable quarterly in arrears. Following the grace period, both interest and principal are payable on a quarterly basis.

Subject to certain conditions precedent, the Loan Agreement proceeds will be released by SOFINEX upon request of the Company and/or Belgian Volition in amounts of up to approximately US\$298,000 (€250,000) per six month period until June 30, 2019, following a reciprocal cash payment by Belgian Volition to Volition America. No additional amounts will be disbursed after June 30, 2019. The Loan Agreement includes periodic reporting obligations by Volition and Belgian Volition as well as certain other covenants and conditions, and events of default permitting acceleration of the outstanding obligations by SOFINEX.

The foregoing summary of the Loan Agreement does not purport to summarize all terms and conditions thereof and is qualified in its entirety by reference to Exhibit 10.1 filed herewith.

Item 8.01 Other Events.

On September 21, 2017, the Company issued a press release announcing the entering into of the unsecured Loan Agreement and highlighting the other significant loans and non-repayable grants received by Belgian Volition during the previous twelve months. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
<u>10.1</u>	Unsecured Credit Agreement dated September 20, 2017 by and among VolitionRx Limited, Belgian Volition SPRL and SOFINEX (English translation of French original).
<u>99.1</u>	Press Release of VolitionRx Limited dated September 21, 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VOLITIONRX LIMITED

Date: September 21, 2017

By: /s/ Cameron Reynolds
Cameron Reynolds
Chief Executive Officer & President

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
<u>10.1</u>	Unsecured Credit Agreement dated September 20, 2017 by and among VolitionRx Limited, Belgian Volition SPRL and SOFINEX (English translation of French original).
<u>99.1</u>	Press Release of VolitionRx Limited dated September 21, 2017.

Unofficial English Translation of a French Document

UNSECURED CREDIT AGREEMENT

BETWEEN

The S.A. (limited liability company) *Wallonne de Financement à l'Exportation et de l'Internationalisation des Entreprises Wallonnes*, abbreviated as "SOFINEX," incorporated by authentic act of September 18, 2003 published in the A.M.B. of September 30, 2003 under number 100737, with headquarters located at 4000 LIEGE, Avenue Maurice Destenay, 13 (ECB no. 860.662.588) and acting in the name and on behalf of SOWALFIN, which itself is on a delegated assignment for the WALLOON REGION,

Represented here by Ms. Anne Vereecke and Mr. Bernard Liebin, Director and Managing Director respectively,

Hereinafter referred to as SOFINEX,

Party of the first part,

AND

The SPRL BELGIAN VOLITION with corporate headquarters located at 5032 ISNES, RUE PHOCAS LEJEUNE, 22 registered at Banque Centrale Carrefour, under BCE number 0891006861

Represented here in accordance with the Statutes by:

-

-

And VOLITIONRX LIMITED, with corporate headquarters located at 228208 Singapore – Scotts Road #24-05 Shaw Centre

-

-

Jointly and severally

Hereinafter referred to as the "Borrowers",

Party of the second part,

The parties of the second part are committed jointly and severally with regard to the common interests that they share, namely the successful fulfillment projects developed by BELGIAN VOLITION SPRL and VOLITIONRX LIMITED and their beneficial effects on the growth of their businesses.

THE PARTIES AGREE AS FOLLOWS:

CHAPTER I - CREDIT TERMS AND CONDITIONS

Section 1. Credit Terms and Conditions

1.01 Amount

Subject to the performance of the conditions precedent provided for in section 3 below, SOFINEX provides Borrowers who accept credit in the amount of EUR 1,000,000.00 (one million euros).

1.02 Term

This credit is granted for a period of 7 years, including a grace period of 2 years.

1.03 Withdrawal period and release of funds

The credit withdrawal period begins upon signing of this Agreement and will expire on 06/30/2019.

SOFINEX will release funds in the amount of €250,000 per six month period, alternately with a contribution on own group funds in advance of an identical amount.

SOFINEX will release the funds as provided above, subject to compliance with the terms of this Agreement and in particular with the conditions precedent set out in section 3 of this Agreement, on the account that will be communicated by the Borrowers in the withdrawal request letter.

Said withdrawal request will be sent by letter, fax or email to SOFINEX, at least 3 working days before the day requested for the withdrawal.

Any withdrawal must constitute at least 10% (ten percent) of the credit amount and at least EUR 10,000.- (ten thousand euros).

If on the date of 06/30/2019, the entirety of the credit has not been debited, for any reason whatsoever, SOFINEX is released from any obligation of payment of the remaining balance due, the right to the credit is thus limited to the amounts actually withdrawn.

1.04 Interest rates

The interest rate of the credit is fixed at 4.50 % per year.

1.05 Interest

Until the end of the quarter of the last withdrawal date, interest on the amounts withdrawn is calculated quarterly by SOFINEX. The interest must be paid by the Borrowers, at the end of each calendar quarter.

At the expiration of the withdrawal period, interest is payable quarterly in arrears, on the outstanding principal owed, on March 31, June 30, September 30 and December 31 of each year, by direct debit, as specified in the reimbursement plan attached to this Agreement, which forms an integral part hereof.

Interest calculations are made on the basis of actual years composed of three hundred and sixty-five days.

1.06 Repayment Terms

Taking into account the 2-year grace period granted, the 1st repayment of principal will take place on 12/31/2019.

The reimbursement plan attached to this Agreement, which constitutes an integral part hereof, contains the dates and amounts of the different maturity dates of the principal.

1.07 Domiciliation of Payments

All payments to SOFINEX must be carried out by direct debit.

To this end, the Borrowers agree to sign the Sepa domiciliation mandate that was sent to them and return it to SOFINEX.

Section 2. Purpose of Credit

~~This~~ credit is intended to partially finance the creation and the development of a subsidiary in the United States which will be owned 100% by BELGIAN VOLITION SPRL.

Section 3. Conditions Precedent

3.01 This Agreement is concluded subject to the prior fulfillment of the conditions precedent:

Increase in the capital of BELGIAN VOLITION SPRL in the amount of minimum 7 Million euros fully subscribed, and paid. In this regard, a copy of the certificate of capital increase will be transmitted to SOFINEX.

A copy of the articles of incorporation of the subsidiary, VOLITION AMERICA Inc. will be provided.

~~Failure~~ to execute the conditions precedent within a period of 6 months from the signing date of this Agreement, SOFINEX will be discharged from any obligation arising herein and this Agreement will be deemed null and void as a result.

Section 4. Early Repayment

~~The~~ Borrowers will have the right to voluntarily repay all or part of the principal on an interest payment due date with a minimum of 3 months' notice. Any repayment must be at least 10% (ten percent) of the amount of the balance remaining and a minimum of EUR 10,000 (ten thousand euros).

In the event of non-compliance with the terms and conditions listed above, SOFINEX is entitled to claim an indemnity corresponding to 3 months of interest calculated on the outstanding balance of the credit amount, at the time of the advanced repayment, at the rate in effect on this date.

Section 5. Late Interest

~~Without~~ prejudice to the application of the immediate repayment clauses, nor SOFINEX's right to proceed with the recovery by any legal means:

Any principal amount or incidental charge, unpaid on its contractual due date, automatically and as of right, carries interest at the effective rate of the credit on the date of the missed due date plus 6.00% per annum, from the date of the conventional maturity date until the day of actual payment;

Failing payment of interest on the due date, without notice, an interest surcharge of 0.50% (half a percent), calculated on the amount of the principal claim, which served as the basis for calculating those interest, is payable to SOFINEX, upon the due date, automatically and as of right.

Section 6. Allocation of Payments

6.01 The order for the allocation of payments made by the Borrowers will be the following:

- 1) the costs;
- 2) the late interest calculated per section 5;
- 3) the conventional interest owed;
- 4) the principal.

Section 7. Joint and Several Nature

~~The~~ obligations and undertakings in this Agreement are joint and several between the Borrowers, and their eventual beneficiaries, in the case of a modification of the social structure (assignment, splitting-up, transfer, etc.). This joint and several nature is to be interpreted as broadly as possible.

SOFINEX can, specifically, seek the recovery of the total amount payable from the Borrowers' beneficiaries.

CHAPTER II - VARIOUS BORROWER COMMITMENTS

Section 8. Obligation of Information

~~The~~ Borrowers will provide to SOFINEX, on an annual basis and/or upon the first request of the latter, a detailed summary table of bank lines of credit and/or loans which it has as well as all of the real or personal security interests conferred.

An updated table will thus be attached each year to the annual accounts that it will communicate to SOFINEX.

~~During~~ the term of this Agreement, the Borrowers undertake to authorize SOFINEX, its auditor or one of its delegates, to proceed at any time with the review and audit of the accounts, company documents and compliance with the present Agreement, by guaranteeing to provide access at an agreed upon date and time to the company and its premises and ensuring any aid and assistance to facilitate their auditing mission by producing all of the company's books and accounting documentation. Costs relating to the intervention of the auditor mandated by SOFINEX will be at the Borrowers' expense.

Section 9. Accounting and Financial Documents

~~The~~ Borrowers' accounts must be maintained in accordance with the relevant legal provisions and must meet the standards set out by the Commission of Accounting Standards.

9.02 Throughout the term of this Agreement, the Borrowers agree to:

~~Send~~ on a semi-annual basis within 60 days of end of the six-month period, a detailed accounting statement for the Group.

~~Send~~ annually, within six months of the end of the fiscal year, their annual accounts drawn up according to the accounting standards in force as well as a copy of the management report of the Board of Directors and, where appropriate, the auditor's report.

~~Send~~ the accounts for the subsidiary VOLITION AMERICA Inc. and a report on the development of the Group annually.

~~Authorize~~ its accountant, chartered accountant, auditor or any other agent to transmit to SOFINEX any information required.

The accounts or other information which SOFINEX would have had knowledge of will be used only to assess the financial situation of the Borrowers and honor their commitments.

Section 10. Other Commitments

10.01 The Borrowers agree to:

~~Use~~ this credit for the purposes agreed to in section 2.

~~Maintain~~ the headquarters and a business address for BELGIAN VOLITION SPRL in the Walloon Region for the term of this Agreement.

~~Inform~~ SOFINEX of commitments made or contracts entered into by the companies likely to influence the future and the development of the latter.

~~Subordinate~~ the distribution of dividends, after the grace period, to the total and complete repayment of this credit on the agreed upon due dates.

~~Repay~~ SOFINEX the credit in advance in the event of total or partial resale of the shareholdings in VOLITION AMERICA held by BELGIAN VOLITION SPRL.

~~Not~~ issue dividends during the 2-year grace period.

~~The~~ Borrowers agree not to grant real or personal security interests, nor to contract joint debt commitments with any other companies or individuals without first informing SOFINEX.

10.03 The Borrowers agree upon express request by SOFINEX:

To entrust, in the case of a modification regarding its current situation, its accounts to an accountant, chartered accountant or a trustee approved by SOFINEX;

To entrust the control of its annual accounts, in the case of a modification regarding its current situation, to an auditor approved by SOFINEX.

CHAPTER III - ACCELERATION CLAUSES

Section 11. Acceleration Clauses

SOFINEX has the right to suspend or revoke, with immediate effect and without formal notice, and to require immediate reimbursement of the credit, in principal and interest, in any of the following cases:

In the event of accelerated repayment provided for or to be provided for by law;

In the event of insolvency, termination of payment, bankruptcy or liquidation of the Borrowers or any one of them, receivership or seizure of its property, or, in general, in the case of any procedure or regulation by which the assets of the Borrowers or any one of them would be placed under direct or indirect control of its creditors, or of the court or any commission constituted for that purpose, as well as in the case of a stay of payment or settlement with its creditors to which SOFINEX would not participate;

If any of the following circumstances occur in the management of the Borrowers or any one of them:

Total or partial cessation or substantial modification of the activity, including the:

dissolution, winding up, change of legal form or of company objective, designation of a provisional administrator;

merger, split, contribution or transfer of a universality or branch of activity.

Death, absence, deed or action that could impair the civil or legal capacity;

Disagreement between directors, officers, associates or managers or inability to manage the legal person due to the judicial arrest of one of them;

Substantial modification of the shareholdings without the prior agreement of SOFINEX.

In the case of a capital reduction or distribution of all or part of the reserves without prior written agreement of SOFINEX;

In the event of a notice of an order to pay or a seizure or non-compliance of commitment of any kind resulting from other funding obtained (credit, borrowing, ...) with an organization other than SOFINEX, resulting in the payment of this debt before its expiry date or in the case of delays with regard to the NSSO, VAT or the professional withholding tax;

In the case of immediate payment of another credit from SOFINEX or from another financial organization;

If it results from accounts, whether published or not, of an interim accounting situation approved by the Board of Directors or an expert, where, after prior application of the necessary depreciation and provisions, the cumulative losses of the Borrowers or any one of them reach half of its own funds (capital, reserves and carry-over).

SOFINEX reserves the right to terminate the credit before its term, by notice of 15 days by registered letter, in all other cases where the Borrowers or one of them is in default of fulfilling any condition or obligation of any kind arising out of this Agreement or of any other obligation owed to SOFINEX, including:

In the case of non-compliance with the provisions of sections 8 to 10 of Chapter II "Various Borrower Commitments";

In the event of non-payment on the scheduled dates of all sums owing to SOFINEX, without prejudice to what is provided for in section 5 "Late interest";

in the event where the Borrowers or one of them does not fulfill the obligations imposed on it by the law, in particular by companies law, accounting law, regulations in the field of urban planning or the law governing the exercise of its business activities;

in the event that the Borrowers award any advance whatsoever to their shareholders, directors or related company(s) without the prior written approval of SOFINEX.

CHAPTER IV - MISCELLANEOUS

Section 12. Applicable Law - Disputes

12.01 This contract is governed exclusively by Belgian law.

The nullity or irregularity affecting any of the clauses of this Agreement shall not entail the nullity of the entire contract.

All disputes in respect of this Agreement are within the exclusive jurisdiction of the Courts and Tribunals within the jurisdiction of the headquarters of SOFINEX.

Section 13. Election of Domicile and Correspondence

13.01 The Borrowers elect the common domicile of the corporate headquarters of BELGIAN VOLITION SPRL;

All correspondence is considered to be validly addressed, unless otherwise indicated, when sent to 5032 ISNES, RUE PHOCAS LEJEUNE, 22.

Executed in Liege, September 20, 2017, in three original copies, with each party acknowledging having received an original copy.

S.A. SOFINEX

/s/ Anne Vereecke
Anne Vereecke
Administrator

/s/ Bernard Liebin
Bernard Liebin
Managing Director

BELGIAN VOLITION SPRL (*)

/s/ Gaëtan Michel
Gaëtan MICHEL
Manager

/s/ Rodney Rootsart
Rodney ROOTSAERT
Manager

VOLITIONRX LIMITED (*)

/s/ Cameron Reynolds
Cameron REYNOLDS
Chief Executive Officer & President

/s/ Dr. Martin Faulkes
Dr. Martin FAULKES
Director

(*) Each signature must be preceded by the notice: "Read and Approved."

REPAYMENT TABLE

Subsidiary: SOFINEX
 Amount of the Agreement **€ 1,000,000.00**

Customer BELGIAN VOLITION SPRL – VOLITIONRX LIMITED
 Jointly
 RUE PHOCAS LEJEUNE, 22
 5032 ISNES

Third party client n°: 020903
 Type of loan: Unsecured Loan
 Loan n°: 20903
 Purpose of the loan: Creation of subsidiary
 Rate of the Agreement: 4.50 %
 Total term of the loan: 7 years
 Term of the grace period: 2 years

		Amount	Principal	Interest	Remaining Balance Due
9/30/2017	Due date	*	€ 0.00	*	€ 1,000,000.00
12/31/2017	Due date	*	€ 0.00	*	€ 1,000,000.00
3/31/2018	Due date	*	€ 0.00	*	€ 1,000,000.00
6/30/2018	Due date	*	€ 0.00	*	€ 1,000,000.00
9/30/2018	Due date	*	€ 0.00	*	€ 1,000,000.00
12/31/2018	Due date	*	€ 0.00	*	€ 1,000,000.00
3/31/2019	Due date	*	€ 0.00	*	€ 1,000,000.00
6/30/2019	Due date	*	€ 0.00	*	€ 1,000,000.00
9/30/2019	Due date	*	€ 0.00	*	€ 1,000,000.00
12/31/2019	Due date	€ 61,342.47	€ 50,000.00	€ 11,342.47	€ 950,000.00
3/31/2020	Due date	€ 60,658.22	€ 50,000.00	€ 10,658.22	€ 900,000.00
6/30/2020	Due date	€ 60,097.26	€ 50,000.00	€ 10,097.26	€ 850,000.00
9/30/2020	Due date	€ 59,641.10	€ 50,000.00	€ 9,641.10	€ 800,000.00
12/31/2020	Due date	€ 59,073.97	€ 50,000.00	€ 9,073.97	€ 750,000.00
3/31/2021	Due date	€ 58,321.92	€ 50,000.00	€ 8,321.92	€ 700,000.00
6/30/2021	Due date	€ 57,853.43	€ 50,000.00	€ 7,853.43	€ 650,000.00
9/30/2021	Due date	€ 57,372.60	€ 50,000.00	€ 7,372.60	€ 600,000.00
12/31/2021	Due date	€ 56,805.48	€ 50,000.00	€ 6,805.48	€ 550,000.00
3/31/2022	Due date	€ 56,102.74	€ 50,000.00	€ 6,102.74	€ 500,000.00
6/30/2022	Due date	€ 55,609.59	€ 50,000.00	€ 5,609.59	€ 450,000.00
9/30/2022	Due date	€ 55,104.11	€ 50,000.00	€ 5,104.11	€ 400,000.00
12/31/2022	Due date	€ 54,536.99	€ 50,000.00	€ 4,536.99	€ 350,000.00
3/31/2023	Due date	€ 53,883.56	€ 50,000.00	€ 3,883.56	€ 300,000.00
6/30/2023	Due date	€ 53,365.75	€ 50,000.00	€ 3,365.75	€ 250,000.00
9/30/2023	Due date	€ 52,835.62	€ 50,000.00	€ 2,835.62	€ 200,000.00
12/31/2023	Due date	€ 52,268.49	€ 50,000.00	€ 2,268.49	€ 150,000.00
03/31/2024	Due date	€ 51,682.88	€ 50,000.00	€ 1,682.88	€ 100,000.00
06/30/2024	Due date	€ 51,121.92	€ 50,000.00	€ 1,121.92	€ 50,000.00
09/30/2024	Due date	€ 50,567.12	€ 50,000.00	€ 567.12	€ 0.00

€ 1,000,000.00

VolitionRx Limited Awarded \$1.5 Million in Non-Dilutive Funding

ISNES, Belgium, September 21, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced that it has been awarded a loan and a non-repayable grant totaling \$1.5 million from SOFINEX and the Walloon Region, Belgium. This is in addition to the \$947,000 in loans previously provided by Namur Invest over the last 12 months, aggregating to approximately \$2.45 million.

Dr. Gaetan Michel, Chief Executive Officer of Volition’s subsidiary, Belgian Volition SPRL, commented, “We are delighted with the financial support that we continue to receive from our local agencies SOFINEX and Namur Invest, as well as the Walloon Region, Belgium. We are committed to the region and plan to recruit even more of the talented scientists in the area. This funding will support our continued research and development activities towards what we hope will be life-saving cancer diagnostic tests.”

David Vanston, Chief Financial Officer of Volition, commented, “It is a key part of our financing strategy to actively seek non-dilutive funding as this provides additional cash on favorable terms to support the Company’s continued development.”

SOFINEX, a public organization focused on the internationalization of Walloon companies and encouraging exports throughout the world, has provided an approximate \$1.2 million (€1 million) unsecured loan to Volition and Belgian Volition. The loan was entered into on September 20, bears interest at 4.5% per year with favorable repayment terms over seven years, and includes a two-year grace period for principal repayment. The purpose of the loan is to support the development of Belgian Volition’s subsidiary, Volition America Inc., who announced in July its participation in a large 13,500 subject Colorectal Cancer Screening study in the U.S. This study is to be conducted in conjunction with the Great Lakes New England Clinical Validation Center funded by the National Cancer Institute’s (NCI) Early Detection Research Network (EDRN).

Belgian Volition has also received a commitment last week, from the Walloon Region, Belgium to receive an additional non-repayable cash grant of approximately \$294,000 (€245,520) as a contribution towards the cost of the new custom-built research and development facility in the Crealys Science Park, Isnes, in the Walloon region of Belgium.

Namur Invest, a public-private partnership which supports the development of companies in the Walloon region, previously provided unsecured loans in October 2016 and May 2017 totaling approximately \$947,000 (€790,000) to Belgian Volition, bearing interest at 4-4.85% per year with favorable repayment terms over 3.5-7 years to help fund Volition’s continued research and development efforts.

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics[®], which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

As cancer screening programs become more widespread, Volition’s products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (<http://www.volitionrx.com>) or connect with us via:

Twitter: <https://twitter.com/volitionrx>

LinkedIn: <https://www.linkedin.com/company/volitionrx>

Facebook: <https://www.facebook.com/VolitionRx/>

YouTube: <https://www.youtube.com/user/VolitionRx>

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Day, Volition <u>L.day@volitionrx.com</u> +44 (0)7557 774620	Scott Powell, Volition <u>S.powell@volitionrx.com</u> +1 (646) 650 1351
Tirth Patel, Edison Advisors <u>tpatel@edisongroup.com</u> +1 (646) 653 7035	Rachel Carroll, Edison Advisors <u>rcarroll@edisongroup.com</u> +44 (0)20 3077 5711

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ®, Nu.Q™ and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "\$" refer to the legal currency of the United States of America.